EFL 192 Pill - white round
Generic Name: eflornithine
Pill with imprint EFL 192 is White, Round and has been identified as Iwilfin 192 mg. It is supplied by US WorldMeds, LLC.
Iwilfin is used in the treatment of Neuroblastoma and belongs to the drug class miscellaneous antineoplastics. Iwilfin 192 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for EFL 192

Iwilfin
- Generic Name
- eflornithine
- Imprint
- EFL 192
- Strength
- 192 mg
- Color
- White
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- US WorldMeds, LLC
- National Drug Code (NDC)
- 78670-0150
See also:
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Oncovin
Oncovin is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Platinol
Platinol is used for bladder cancer, blood cell transplantation, bone marrow transplantation, brain ...
Cytoxan Lyophilized
Cytoxan Lyophilized is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast ...
Vincristine
Vincristine is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Cyclophosphamide
Cyclophosphamide is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, brain ...
More about Iwilfin (eflornithine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.